Objective To investigate the changes in the cytokine profiles of chronic hepatitis B(CHB)patients undergoing antiviral treatment.Methods Hepatitis B e antigen(HBeAg)-positive patients were treated with Pegylated inter...Objective To investigate the changes in the cytokine profiles of chronic hepatitis B(CHB)patients undergoing antiviral treatment.Methods Hepatitis B e antigen(HBeAg)-positive patients were treated with Pegylated interferon(PEGIFN)and entecavir(ETV).Clinical biochemistry and cytokines were detected at baseline and every 3 months.Results In all,200 patients completed 48 weeks of treatment,100 in the PEG-IFN group and 100 in the ETV group.During 3–6 months of treatment,compared with baseline,the PEG-IFN group showed a significant decrease in interferon-gamma(IFN-γ),interleukin-17 A(IL-17 A),interleukin-6(IL-6),interleukin-10(IL-10),and transforming growth factor beta(TGF-β)(P<0.001)and a significant increase in interferon-alpha 2(IFN-α2)(P<0.001).In the ETV group,IL-10 and TGF-β1 decreased significantly(P<0.001).After 3 months,the levels of IFN-α2,IL-17 A,and tumor necrosis factor-alpha(TNF-α)in the PEGIFN group were significantly higher than those in the ETV group(P<0.01).The levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group(P<0.01).After 6 months,the levels of IFN-α2,IFN-γ,and TNF-αin the PEG-IFN group were significantly higher than those in the ETV group(P<0.01),while the levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group(P<0.01).Compared with ETV,PEG-IFN had higher HBeAg and HBsAg disappearance rates.Conclusion During antiviral therapy,a change in the cytokine profile occurred;in the aspect of immune control and functional cure,PEG-IFN was significantly better than ETV.展开更多
Objective This study aimed to investigate whether cytokine profiles and virological markers might add value in monitoring the effects of peginterferon(PEG-IFN)therapy for hepatitis B e-antigen(HBeAg)positive chronic h...Objective This study aimed to investigate whether cytokine profiles and virological markers might add value in monitoring the effects of peginterferon(PEG-IFN)therapy for hepatitis B e-antigen(HBeAg)positive chronic hepatitis B(CHB).Methods HBeAg positive patients with CHB were treated with PEG-IFN for 48 weeks.Clinical biochemical,and HBV serological indexes,as well as cytokines,were detected at baseline and every12 weeks.Results A total of 116 patients with CHB were enrolled in this study;100 patients completed the 48-week treatment and follow-up,of whom 38 achieved serum HBeAg disappearance,25 achieved HBeAg seroconversion,37 showed HBsAg decreases≥1 log10 IU/mL,9 showed HBsAg disappearance,and 8became HBsAb positive.The cytokine levels at baseline and during treatment were similar between the HBeAg disappearance group and non-disappearance group.The disappearance of HBeAg was independently associated with HBeAg levels at weeks 12 and 24,and with the HBeAg decline at week 24(P<0.05).The HBsAg response was independently associated with HBsAg,the HBsAg decline,HBeAg,the HBeAg decline at week 12,and HBsAg at week 24(P<0.05).Conclusion There was no significant correlation between the response to interferon(IFN)and cytokines during PEG-IFN treatment.The changes in virological markers predicted the response to IFN after 48 weeks.展开更多
基金funded in part by the Beijing Hospitals Authority Clinical medicine Development of special funding support[No.XMLX 201706 and XMLX 202127]Beijing Municipal Science&Technology Commission[No.Z151100004015122]+2 种基金National Science and Technology Major Project of China[No.2017ZX10203202-003,2017ZX10201201-001-006,and 2017ZX10201201-002-006]Beijing Science and Technology Commission[No.D161100002716002]Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals[No.XXZ0302 and XXT28]。
文摘Objective To investigate the changes in the cytokine profiles of chronic hepatitis B(CHB)patients undergoing antiviral treatment.Methods Hepatitis B e antigen(HBeAg)-positive patients were treated with Pegylated interferon(PEGIFN)and entecavir(ETV).Clinical biochemistry and cytokines were detected at baseline and every 3 months.Results In all,200 patients completed 48 weeks of treatment,100 in the PEG-IFN group and 100 in the ETV group.During 3–6 months of treatment,compared with baseline,the PEG-IFN group showed a significant decrease in interferon-gamma(IFN-γ),interleukin-17 A(IL-17 A),interleukin-6(IL-6),interleukin-10(IL-10),and transforming growth factor beta(TGF-β)(P<0.001)and a significant increase in interferon-alpha 2(IFN-α2)(P<0.001).In the ETV group,IL-10 and TGF-β1 decreased significantly(P<0.001).After 3 months,the levels of IFN-α2,IL-17 A,and tumor necrosis factor-alpha(TNF-α)in the PEGIFN group were significantly higher than those in the ETV group(P<0.01).The levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group(P<0.01).After 6 months,the levels of IFN-α2,IFN-γ,and TNF-αin the PEG-IFN group were significantly higher than those in the ETV group(P<0.01),while the levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group(P<0.01).Compared with ETV,PEG-IFN had higher HBeAg and HBsAg disappearance rates.Conclusion During antiviral therapy,a change in the cytokine profile occurred;in the aspect of immune control and functional cure,PEG-IFN was significantly better than ETV.
基金funded in part by Beijing Hospitals Authority Clinical Medicine Development of Special Funding support[XMLX 201706 and XMLX 202127]the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority[XXZ0302 and XXT28]+3 种基金the National Science and Technology Major Project of China[2017ZX10201201-001-006,2017ZX10201201-002-006,and 2018ZX10715-005-003-005]the Beijing Municipal Science&Technology Commission[Z151100004015122]the Beijing Science and Technology Commission[D161100002716002]the Special Public Health Project for Health Development in Capital[2021-1G-4061]
文摘Objective This study aimed to investigate whether cytokine profiles and virological markers might add value in monitoring the effects of peginterferon(PEG-IFN)therapy for hepatitis B e-antigen(HBeAg)positive chronic hepatitis B(CHB).Methods HBeAg positive patients with CHB were treated with PEG-IFN for 48 weeks.Clinical biochemical,and HBV serological indexes,as well as cytokines,were detected at baseline and every12 weeks.Results A total of 116 patients with CHB were enrolled in this study;100 patients completed the 48-week treatment and follow-up,of whom 38 achieved serum HBeAg disappearance,25 achieved HBeAg seroconversion,37 showed HBsAg decreases≥1 log10 IU/mL,9 showed HBsAg disappearance,and 8became HBsAb positive.The cytokine levels at baseline and during treatment were similar between the HBeAg disappearance group and non-disappearance group.The disappearance of HBeAg was independently associated with HBeAg levels at weeks 12 and 24,and with the HBeAg decline at week 24(P<0.05).The HBsAg response was independently associated with HBsAg,the HBsAg decline,HBeAg,the HBeAg decline at week 12,and HBsAg at week 24(P<0.05).Conclusion There was no significant correlation between the response to interferon(IFN)and cytokines during PEG-IFN treatment.The changes in virological markers predicted the response to IFN after 48 weeks.
